ValuEngine Downgrades Opiant Pharmaceuticals (OPNT) to Sell

Share on StockTwits

ValuEngine cut shares of Opiant Pharmaceuticals (NASDAQ:OPNT) from a hold rating to a sell rating in a research report report published on Thursday.

Separately, Cantor Fitzgerald set a $32.00 target price on shares of Opiant Pharmaceuticals and gave the stock a buy rating in a research report on Monday, July 30th.

Shares of Opiant Pharmaceuticals opened at $15.11 on Thursday, reports. Opiant Pharmaceuticals has a 1 year low of $12.75 and a 1 year high of $51.90. The company has a market cap of $46.04 million, a PE ratio of 41.90 and a beta of -0.84.

Opiant Pharmaceuticals (NASDAQ:OPNT) last announced its earnings results on Thursday, August 9th. The technology company reported ($0.52) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.07) by $0.55. Opiant Pharmaceuticals had a negative net margin of 449.52% and a negative return on equity of 640.89%. The company had revenue of $3.15 million for the quarter, compared to analyst estimates of $2.10 million. research analysts anticipate that Opiant Pharmaceuticals will post -5.86 EPS for the current fiscal year.

In other news, Director Thomas T. Thomas sold 2,763 shares of the company’s stock in a transaction that occurred on Friday, May 18th. The shares were sold at an average price of $16.44, for a total transaction of $45,423.72. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Thomas T. Thomas sold 4,300 shares of the company’s stock in a transaction that occurred on Tuesday, May 15th. The stock was sold at an average price of $18.35, for a total transaction of $78,905.00. The disclosure for this sale can be found here. 63.82% of the stock is currently owned by corporate insiders.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.

Further Reading: Earnings Per Share (EPS)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply